D-0953-2020 Class II Terminated

Recalled by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical — Los Angeles, CA

FDA drug recall D-0953-2020 was initiated by Fusion IV Pharmaceuticals, Inc. Dba Axia Pharmaceutical on Jan 15, 2020 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Dec 7, 2023).

Recall details

Product Type
Drugs
Report Date
Mar 11, 2020
Initiation Date
Jan 15, 2020
Termination Date
Dec 7, 2023
Voluntary/Mandated
Voluntary: Firm initiated

Product description

Glutathione Injection,GLUTATHIONE 200MG/ML INJECTABLE For IV, IM Use, Refrigerate, 30 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-1231-3

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic

Code information

Lot #: 10212019+53138, Exp 11/19/2020; 10302019+53172, Exp 1/28/2020; 11122019+53225, Exp 2/10/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0953-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0953-2020. Report a data issue: hello@regdatalab.com.